Counter intuitive

That's how I see the argument by some Cellestis shareholders - they say that management have neglected marketing to both the medical community and the investment community and that this "failure" is reflected in both sales and share price.

Cellestis management will readily concede that they have had done little if any marketing in Australia so how does this happen, where sales are ~50% of the total market?

Perhaps global success lies in less not more marketing...